To hear about similar clinical trials, please enter your email below
Trial Title:
Multi-omics Approach of Risk Stratification for Patients With de Novo Acute Myeloid Leukemia
NCT ID:
NCT05983172
Condition:
Acute Myeloid Leukemia
Conditions: Official terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Conditions: Keywords:
Acute myeloid leukemia
Machine learning
Artificial intelligence
Risk stratification
Study type:
Observational [Patient Registry]
Overall status:
Enrolling by invitation
Study design:
Time perspective:
Other
Summary:
The investigators will use machine learning to identify features on bone marrow smears
and select features that are related to gene mutations, gene expression, or prognosis.
The investigators will then use genome-wide transcriptomic profiling to investigate gene
expression that is associated with patients' outcomes. The investigators will design a
next-generation sequencing panel with unique molecular index and assess its feasibility
and robustness in detecting measurable residual disease and optimize the
panel/platform/bioinformatic pipeline. Finally, The investigators will use machine
learning to integrate bone marrow smear features, gene mutations, gene expression, and
measurable residual disease to construct a comprehensive risk assessment system that is
based on multi-omics data. The investigators believe that such a platform will help
physicians to design the most appropriate treatment strategies for individual patients,
not only advancing the concept of precision medicine but also improving patients'
prognoses.
Criteria for eligibility:
Study pop:
Adult patients with acute myeloid leukemia
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Diagnosed with acute myeloid leukemia at the National Taiwan University Hospital
2. Ever enrolled in 201802021RINC、202109078RINB、201709072RINC
Exclusion Criteria:
Nil
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
National Taiwan University Hospital
Address:
City:
Taipei
Zip:
100
Country:
Taiwan
Start date:
August 2023
Completion date:
July 2026
Lead sponsor:
Agency:
National Taiwan University Hospital
Agency class:
Other
Source:
National Taiwan University Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05983172
